Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- BBOX -13.9%, BOOT -10.6%, MANH -7.7%, PBI -5.8%, BABY -5.2%, JCI -4.5%, MTCH -4.4%, (also sells non-dating business The Princeton Review to ST Unitas)
- ARAY -4.3%, TNAV -3.4%, ADP -3%, D -3%, UNVR -2.7%, (announces the sale of 15,000,000 shares of common stock by selling shareholders; sees Q4 EPS $0.23-0.27 vs $0.10 Capital IQ Consensus Estimate; revs $1.8-1.85 bln vs $1.90 bln Capital IQ Consensus Estimate )
- ILMN -2.4%, BBVA -2.3%, KTCC -1.8%, EA -1.7%, MDC -1.4%, MO -1.3%, NEU -1.2%, MSTR -1.1%, CACC -1.1%, OMN -1.1%, PPL -1%
Other news:
- CATB -65.6% (Catabasis Pharmaceuticals announces top-line safety and efficacy results for Part B of the MoveDMD trial of edasalonexent (CAT-1004) for the treatment of Duchenne muscular dystrophy)
- SGYP -12% (prices 20,325,204 common stock offering at $6.15/share)
- CCJ -10.6% (announces that Tokyo Electric Power Company Holdings has issued a termination notice for a uranium supply contract with Cameco)
- GALE -10.3% (Galena Biopharma announces Pres/CEO Mark W. Schwartz will resign effective today and the evaluation of strategic alternatives)
- UNVR -2.7% (prices previously announced public offering of 15,000,000 shares of Univar's common stock by selling shareholders at $29.00/share)
- MCRN -2.4% (prices offering of 12 mln shares of common stock by selling shareholders at $16.25 per share)
- SN -2% (prices 10 mln shares of common stock at $12.50 per share)
- FHB -1.1% (prices secondary offering of 25 mln shares by selling shareholders at $32.00 per share)
- TMHC -0.8% (prices offering of 10 mln shares of common stock at $19.00 per share)
Analyst comments:
- MBLY -3.6% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
- NCMI -2.8% (downgraded to Underperform at Credit Suisse)
- GLW -1.7% (downgraded to Mkt Perform from Outperform at Bernstein)
- IMAX -0.6% (downgraded to Neutral from Outperform at Credit Suisse)